Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

M. Marre; S. P. Marso; N. R. Poulter; S. E. Nissen; M. A. Nauck; B. Zinman; G. H. Daniels; S. Pocock; W. M. Steinberg; R. M. Bergenstal; J. F E Mann; L. Steen Ravn; K. Brown Frandsen; A. C. Moses; J. B. Buse

doi:10.1016/s1957-2557(15)30080-8

Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Translated title of the contribution: Design of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)

M. Marre, S. P. Marso, N. R. Poulter, S. E. Nissen, M. A. Nauck, B. Zinman, G. H. Daniels, S. Pocock, W. M. Steinberg, R. M. Bergenstal, J. F E Mann, L. Steen Ravn, K. Brown Frandsen, A. C. Moses, J. B. Buse

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

Translated title of the contribution	Design of the Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER® trial)
Original language	French
Pages (from-to)	316-328
Number of pages	13
Journal	Medecine des Maladies Metaboliques
Volume	9
Issue number	3
DOIs	https://doi.org/10.1016/s1957-2557(15)30080-8
State	Published - 2015

Keywords

GLP-1 receptor agonists
Liraglutide
cardiovascular.
type 2 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Nutrition and Dietetics
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/s1957-2557(15)30080-8

Cite this

Marre, M., Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., Steen Ravn, L., Brown Frandsen, K., Moses, A. C., & Buse, J. B. (2015). Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®). Medecine des Maladies Metaboliques, 9(3), 316-328. https://doi.org/10.1016/s1957-2557(15)30080-8

Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®). / Marre, M.; Marso, S. P.; Poulter, N. R. et al.
In: Medecine des Maladies Metaboliques, Vol. 9, No. 3, 2015, p. 316-328.

Research output: Contribution to journal › Article › peer-review

Marre, M, Marso, SP, Poulter, NR, Nissen, SE, Nauck, MA, Zinman, B, Daniels, GH, Pocock, S, Steinberg, WM, Bergenstal, RM, Mann, JFE, Steen Ravn, L, Brown Frandsen, K, Moses, AC & Buse, JB 2015, 'Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)', Medecine des Maladies Metaboliques, vol. 9, no. 3, pp. 316-328. https://doi.org/10.1016/s1957-2557(15)30080-8

@article{e62c62ae39aa418d96ff75a737921af9,

title = "Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER{\textregistered})",

abstract = "LEADER{\textregistered} (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER{\textregistered} design is presented here.",

keywords = "GLP-1 receptor agonists, Liraglutide, cardiovascular., type 2 diabetes",

author = "M. Marre and Marso, {S. P.} and Poulter, {N. R.} and Nissen, {S. E.} and Nauck, {M. A.} and B. Zinman and Daniels, {G. H.} and S. Pocock and Steinberg, {W. M.} and Bergenstal, {R. M.} and Mann, {J. F E} and {Steen Ravn}, L. and {Brown Frandsen}, K. and Moses, {A. C.} and Buse, {J. B.}",

year = "2015",

doi = "10.1016/s1957-2557(15)30080-8",

language = "French",

volume = "9",

pages = "316--328",

journal = "Medecine des Maladies Metaboliques",

issn = "1957-2557",

publisher = "Elsevier Masson",

number = "3",

}

TY - JOUR

T1 - Evaluation des effets cardiovasculaires du liraglutide

T2 - conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

AU - Marre, M.

AU - Marso, S. P.

AU - Poulter, N. R.

AU - Nissen, S. E.

AU - Nauck, M. A.

AU - Zinman, B.

AU - Daniels, G. H.

AU - Pocock, S.

AU - Steinberg, W. M.

AU - Bergenstal, R. M.

AU - Mann, J. F E

AU - Steen Ravn, L.

AU - Brown Frandsen, K.

AU - Moses, A. C.

AU - Buse, J. B.

PY - 2015

Y1 - 2015

N2 - LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

AB - LEADER® (Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcomes results) is a clinical trial evaluating the long-term effect of liraglutide on the incidence of cardiovascular events among 9 340 patients with type 2 diabetes at high cardiovascular risk. The primary endpoint was the occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Patients, naive or treated with conventional diabetes therapy, were randomized 1:1 to receive liraglutide or placebo, and followed up to 5 years after randomization. LEADER® design is presented here.

KW - GLP-1 receptor agonists

KW - Liraglutide

KW - cardiovascular.

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84942887765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942887765&partnerID=8YFLogxK

U2 - 10.1016/s1957-2557(15)30080-8

DO - 10.1016/s1957-2557(15)30080-8

M3 - Article

AN - SCOPUS:84942887765

SN - 1957-2557

VL - 9

SP - 316

EP - 328

JO - Medecine des Maladies Metaboliques

JF - Medecine des Maladies Metaboliques

IS - 3

ER -

Evaluation des effets cardiovasculaires du liraglutide: conception et donnees de base de l'etude Liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER®)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this